[Roche](https://www.gene.com/good/giving/corporate-giving)

Rolling

No fixed award; funding and collaboration terms are negotiated per partnership opportunity.

Roche and Genentech seek global partnerships to advance research, accelerate drug discovery, and develop innovative medicines through collaborative expertise.

Focus areas include AI-driven R&D, neuroscience, cancer immunotherapy, personalized medicine, and other high-impact therapeutic areas.

--- ## Description Roche and Genentech’s partnering program is designed to foster collaborations with companies, academic institutions, and innovators worldwide who share a commitment to transforming patient care. The program emphasizes strategic alliances that leverage mutual expertise to drive scientific breakthroughs and bring innovative medicines to market. Areas of interest include AI-driven research, neuroscience, cancer immunotherapy, personalized medicine, and a broad spectrum of therapeutic and technology domains. The partnership model is built on trust, shared values, and openness, aiming for long-term, impactful collaborations. --- ## Due Dates - Rolling: Proposals and partnership inquiries are accepted year-round. --- ## Funding Amount - There is no predetermined funding amount or award ceiling. Support, investment, and collaboration structures are tailored to each partnership and negotiated based on the proposed opportunity’s scope, stage, and strategic alignment. --- ## Eligibility - Open to: - Companies (biotech, pharma, digital health, AI, and related technology sectors) - Academic and research institutions - Innovators with assets, technologies, or programs in Roche/Genentech’s priority areas - Ideal partners demonstrate: - Best- or first-in-class innovation - A track record or strong potential for scientific or technological breakthrough - Alignment with Roche/Genentech’s mission and values ### Key Areas of Interest - **Therapeutic Areas:** - Oncology and Hematology - Immunology - Infectious Diseases - Neurology - Ophthalmology - Cardiovascular, Renal, and Metabolic Diseases - **Research & Technology Focus:** - Research technologies (e.g., new mechanisms, enabling technologies, targeted delivery, genomic medicine, ML-enabled drug discovery) - Digital and data innovations (e.g., real-world data, AI models, advanced analytics, digital platforms) - **Geographic Focus:** - Global, with dedicated partnering leads for Asia, UK, and other regions --- ## Application Process - Interested parties should submit a proposal or contact the relevant partnering lead via the [Genentech Partner With Us page](https://www.gene.com/partners/partner-with-us). - Proposals can be submitted at any time. - Applicants should clearly articulate: - The innovation or asset - Stage of development - Potential impact for patients and alignment with Roche/Genentech’s focus areas - During partnership discussions, a dedicated Alliance Director is assigned to support collaboration. --- ## Additional Information - Roche and Genentech have a long history of successful collaborations, with approximately half their pipeline and marketed medicines resulting from partnerships. - The program values trust, transparency, and shared goals, aiming for mutually beneficial, enduring relationships. - Examples of collaboration models include licensing, co-development, research alliances, and technology/platform partnerships. --- ## External Links - [Program Overview & Partnering Information](https://www.gene.com/topics/partnering) - [What We Are Looking For](https://www.gene.com/partners/what-we-are-looking-for) - [Submit a Proposal](https://ppdash.my.site.com/pharmalead/s/genentech-pharma-partnering-leads) - [Partner With Us](https://www.gene.com/partners/partner-with-us) - [Contact Page](https://www.gene.com/partners/contacts?topic=partnering) --- ## Contact Information | Name | Area/Role | Email | |------------------------------|--------------------------------------------------|---------------------------------------| | Jean Eric Charoin | Immunology, CVRM & Infectious Diseases | [jean_eric.charoin@roche.com](mailto:jean_eric.charoin@roche.com) | | Michael Scherer | Digital and Data | [michael.scherer.ms3@roche.com](mailto:michael.scherer.ms3@roche.com) | | Rose Damestani | Neurology, Ophthalmology & Rare Diseases | [damestar@gene.com](mailto:damestar@gene.com) | | Iris Lee | Oncology and Hematology | [lee.iris@gene.com](mailto:lee.iris@gene.com) | | Tomas Hejhal | Research Technologies | [tomas.Hejhal@roche.com](mailto:tomas.Hejhal@roche.com) | | Mikio Kasahara | Pharma Partnering Japan | [mikio.kasahara@roche.com](mailto:mikio.kasahara@roche.com) | | Wenjia Li | Pharma Partnering China, Taiwan & Singapore | [wenjia.li@roche.com](mailto:wenjia.li@roche.com) | | Hailey Jung | Pharma Partnering Korea | [hailey_hr.jung@roche.com](mailto:hailey_hr.jung@roche.com) | | Anna Williamson | UK Partnering Lead | [anna.williamson@roche.com](mailto:anna.williamson@roche.com) | | Matthias Rueth | Global Head of Alliance & Asset Management | [matthias.rueth@roche.com](mailto:matthias.rueth@roche.com) |

Partnering

Sign in to see full grant listing